Copyright: IAKW-AG, www.pov.at
Connect with BÜHLMANN at UEG Week 2018
26th United European Gastroenterology Week
BÜHLMANN Laboratories AG
Booth: #X5/36
Oct 20 -24, 2018
Location
Austria Center Vienna (ACV)
Vienna, Austria
BÜHLMANN is Gold Standard for diagnosis and monitoring of IBD patients with a comprehensive test portfolio of calprotectin and TDM rapid tests for biologics. BÜHLMANN offers the FDA cleared market leader BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo for high throughput testing and the rapid Quantum Blue® calprotectin routine POC tests. Quantum Blue® TDM tests offer patients biologics levels within 15 minutes. IBDoc® is the highly successful home use inflammation monitoring solution for patients, using an app that transforms smart phones into a calprotectin test reading device.
BÜHLMANN Highlights at UEG Week 2018:
New Quantum Blue® fCAL user Video
The Quantum Blue® fCAL rapid test offers lateral flow-based quantitative calprotectin testing within 15 minutes. The BÜHLMANN product line covers 3 different test ranges suitable for diagnosis and therapy follow-up of IBD patients. Convenient and safe stool extraction with CALEX® Cap stool extraction device is followed by the quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology.
By loading the video, you agree to YouTube's privacy policy.
Learn more
Poster of Excellence: Patient-near application of Quantum Blue® Therapeutic Drug Monitoring rapid test
P1580, A. I.Lindsjø et. al., Norway
Røseth A., Lindsjô I. et al. compared the CE- marked Point of Care (POC) trough level rapid test using the BÜHLMANN Quantum Blue® reader with an established laboratory test performed by Norwegian physicians. Thereby, a close correlation between both therapeutic drug monitoring tests was observed. In addition, the POC rapid test showed high robustness since a nurse without ordinary lab training can accurately perform it.
Further BÜHLMANN Poster Highlight at UEG Week 2018
Quantum Blue® Therapeutic Drug Monitoring
23.10.2018, 09:00 – 17:00; Poster Session: IBD II (Hall X1)
FDA 510(k) clearance for BÜHLMANN fCAL® ELISA
The BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the FDA and is now commercially available in the US.
IBDoc® – SwissMedtech Award Nominee
At this year’s SwissMedtech Day, BÜHLMANN was nominated to receive the Swiss Medtech Award for presenting IBDoc® to a Jury of medtech and academic reperesentatives. The jury nominated 3 projects for the Swiss Medtech Award 2018, BÜHLMANN Laboratories AG among them.
Get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio:
Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, biologic trough levels (Therapeutic Drug Monitoring) and CRP. Additional trough level assays coming soon!
IBDoc® calprotectin home test for remote monitoring of IBD patients
CALEX® Cap, the new standard in stool extraction
BÜHLMANN fCAL® turbo, the new high troughput, random access fecal Calprotectin assay. Available for virtually all Clinical Chemistry Analyzers, time to result 10 minutes! The new benchmark for routine labs
BÜHLMANN fCAL® ELISA, the gold standard assay for fecal Calprotectin determination